ING Groep NV increased its position in C.R. Bard, Inc. (NYSE:BCR) by 40.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,892 shares of the medical instruments supplier’s stock after acquiring an additional 2,265 shares during the quarter. ING Groep NV’s holdings in C.R. Bard were worth $2,529,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Farallon Capital Management LLC purchased a new stake in C.R. Bard in the 2nd quarter worth about $463,101,000. Renaissance Technologies LLC increased its holdings in C.R. Bard by 35.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,295,600 shares of the medical instruments supplier’s stock worth $409,552,000 after acquiring an additional 338,900 shares during the last quarter. Alpine Associates Management Inc. purchased a new stake in C.R. Bard in the 2nd quarter worth about $265,663,000. Wells Fargo & Company MN increased its holdings in C.R. Bard by 145.1% in the 2nd quarter. Wells Fargo & Company MN now owns 584,240 shares of the medical instruments supplier’s stock worth $184,684,000 after acquiring an additional 345,877 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in C.R. Bard by 363.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 466,183 shares of the medical instruments supplier’s stock worth $147,364,000 after acquiring an additional 365,588 shares during the last quarter. 80.31% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “ING Groep NV Purchases 2,265 Shares of C.R. Bard, Inc. (BCR)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/24/ing-groep-nv-purchases-2265-shares-of-c-r-bard-inc-bcr.html.

C.R. Bard, Inc. (NYSE:BCR) opened at $335.18 on Friday. The firm has a market capitalization of $24,432.06, a PE ratio of 28.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. C.R. Bard, Inc. has a twelve month low of $206.26 and a twelve month high of $336.98.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter last year, the company posted $2.64 EPS. equities research analysts expect that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a $0.26 dividend. The ex-dividend date is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s payout ratio is 13.70%.

In other news, Director David M. Barrett sold 3,344 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $327.31, for a total transaction of $1,094,524.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $322.00, for a total value of $2,700,936.00. The disclosure for this sale can be found here. Insiders sold 191,593 shares of company stock valued at $62,655,513 in the last quarter. Corporate insiders own 0.80% of the company’s stock.

Several brokerages recently weighed in on BCR. Cowen Inc reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Friday, November 3rd. Barclays PLC lifted their target price on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. Finally, Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $303.50.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.